Adhesion GPCRs emerge as a major untapped drug target family
A large multi-author Pharmacological Reviews paper surveys adhesion GPCRs, mechanosensitive receptors tied to neurological, immune, and cardiovascular disease.
Summary
Adhesion G protein-coupled receptors (aGPCRs) are a large family of cell-surface proteins that sense cell-matrix contacts and mechanical forces. This comprehensive review, written by roughly 85 specialists, appears in Pharmacological Reviews (2026). The text supplied for analysis contained only the title, author list, and affiliations, so this summary reflects the review's scope and well-established background rather than its detailed data. aGPCRs have large extracellular regions, a GAIN domain that self-cleaves, and in many cases a tethered peptide agonist. They influence brain development, synapse formation, immunity, bone, heart, and cancer biology. Their pharmacology is still immature, with few approved drugs and many open questions about ligands and signaling. Readers should treat details here as provisional until the full text is checked.
Detailed Summary
Why this matters: G protein-coupled receptors are targets of roughly a third of approved drugs, yet adhesion GPCRs (aGPCRs), the second-largest GPCR class with 33 human members, remain largely unexploited. They link cell adhesion, mechanical force sensing, and intracellular signaling, and mutations in them are linked to human disease. This makes them relevant to aging-related biology in the nervous, immune, skeletal, vascular, and cardiac systems.
What was studied: This is a comprehensive, community-written review in Pharmacological Reviews (2026). It has about 85 authors from structural biology, pharmacology, neuroscience, immunology, cardiovascular research, oncology, and industry, and is led by Tobias Langenhan and Nicole Scholz of Leipzig University. Important caveat: the text provided to me contained only the title, author list, and affiliations, with no body text. The description below therefore reflects the review's evident scope and widely established knowledge of the field, not extracted data from the paper.
Key themes: aGPCRs are typically defined by a long extracellular region with adhesion-type domains and a GPCR autoproteolysis-inducing (GAIN) domain. Many undergo self-cleavage, and a tethered peptide sequence (the Stachel) can act as an internal agonist, which gives them an unusual activation mechanism. Several appear to respond to mechanical force, matrix proteins, or partner proteins on neighboring cells. Established examples include ADGRG1/GPR56 in cortical development, ADGRV1 in hearing and vision (Usher syndrome), ADGRG6/GPR126 in Schwann cell myelination, and latrophilins (ADGRL) in synapse organization. Other members have been studied in immune cell function, vascular and cardiac biology, bone, and tumor behavior, including glioblastoma.
Implications: Recent structural work, particularly cryo-EM structures of aGPCR-G protein complexes, together with synthetic peptide agonists and engineered tools, is opening the way to drug discovery. For physicians and longevity-minded readers, the main message is that these receptors regulate tissue maintenance, neural connectivity, and immune surveillance, all of which change with age. They are plausible long-term therapeutic targets rather than current treatments.
Caveats: Many aGPCRs remain orphan receptors with unconfirmed physiological ligands, signaling is complex and context-dependent, and selective pharmacological tools are scarce. Most evidence comes from cell culture, model organisms, and human genetics, not clinical trials. The details here should be verified against the full review.
Key Findings
- Adhesion GPCRs form a 33-member human receptor class with large adhesive extracellular regions and a self-cleaving GAIN domain.
- Many aGPCRs can be activated by a tethered peptide agonist and may respond to mechanical force.
- aGPCR dysfunction is linked to neurodevelopmental, sensory, immune, and other disorders, as well as cancer biology.
- Therapeutic exploitation is early-stage, limited by orphan status, complex signaling, and few selective ligands.
Methodology
This is a large collaborative narrative review in Pharmacological Reviews, written by about 85 experts across disciplines. The text supplied contained only metadata and author affiliations, so the specific sections, search methods, and data synthesized could not be assessed.
Study Limitations
The full body text was not provided, so this summary draws on the review's scope and general field knowledge, not on its detailed content. Reviews also reflect author selection and interpretation, and much aGPCR evidence comes from preclinical models. Specific claims should be verified against the original article.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: